Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1625
    -0.0058 (-0.50%)
     

  • GBP/USD

    1.2390
    -0.0049 (-0.39%)
     

  • Bitcoin GBP

    51,832.22
    +632.30 (+1.23%)
     

  • CMC Crypto 200

    1,334.09
    +21.47 (+1.58%)
     

  • S&P 500

    4,988.72
    -22.40 (-0.45%)
     

  • DOW

    38,017.01
    +241.63 (+0.64%)
     

  • CRUDE OIL

    83.45
    +0.72 (+0.87%)
     

  • GOLD FUTURES

    2,412.20
    +14.20 (+0.59%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Novartis's Alcon eye-care unit to enter Swiss index after spin off

Reuters
FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday.

Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said.

Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.

Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.

(Reporting by John Revill; Editing by Edmund Blair)